Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This meta-analysis reports that trastuzumab deruxtecan is effective and has an acceptable safety profile for treating HER2-low or positive advanced breast cancer, although further research is recommended to support individualized treatment strategies.

This study found that patient-reported outcomes were similar between neoadjuvant endocrine therapy and chemotherapy in premenopausal breast cancer patients, but future perspective was significantly better with endocrine therapy.

This study found that using renin-angiotensin system-targeting antihypertensive agents or statins is associated with reduced serum HER2 levels, which may influence the risk of metabolic syndrome in women.

This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.

This study observed that dalpiciclib is associated with fewer adverse events like diarrhea and hepatotoxicity compared to other CDK4/6 inhibitors, potentially offering better patient-perceived safety and quality of life.

This study found that the novel anti-HER2 antibody RC48 demonstrated promising activity and manageable safety in patients with HER2-overexpressing, advanced gastric or gastroesophageal junction cancer after at least two prior chemotherapy lines.

This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.

This study identified common symptoms and side effects experienced by women with hormone receptor-positive, HER2-negative advanced breast cancer, including fatigue, hair loss, and impacts on daily activities and mobility.

This study found that sacituzumab govitecan improved health-related quality of life in most areas for patients with HR+/HER2− metastatic breast cancer compared to chemotherapy, except for increased diarrhea, supporting its use as a treatment option.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

This study found that participants with HR-positive/HER2-negative advanced or metastatic breast cancer treated with sacituzumab govitecan had better quality of life and longer survival compared to standard chemotherapy recipients.

This article highlights exosome-based targeted drug delivery using DARPin G3 proteins as a promising approach for treating aggressive HER2-positive breast cancer but reports no new clinical results.

In this study, EC chemotherapy was found to be noninferior to TC in causing grade 3 or 4 neutropenia among HR+/HER2-negative breast cancer patients, but EC was associated with more other adverse events.

This case report presents an instance of tufted hair folliculitis in a woman treated with trastuzumab, highlighting a previously unreported skin side effect of this selective HER2 inhibitor.

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

This study reported that subcutaneous trastuzumab improved certain symptoms and did not negatively impact health-related quality of life in patients with early or metastatic HER2-overexpressing breast cancer.

This study reports that health-related quality of life was generally maintained, and sometimes improved, in patients with HR+/HER2- advanced or metastatic breast cancer treated with palbociclib, compared to monotherapy, across various study types.

This study found that Sudanese breast cancer survivors receiving hormonal or HER2-targeted therapies had better quality of life compared to those on conventional therapy.

This study concluded that while CDK4/6 inhibitors, used to treat HR+ HER2- metastatic breast cancer, generally did not worsen health-related quality of life, they were associated with increased patient-reported issues like diarrhea and hair loss upset.

This study found that 93% of patients treated with adjuvant Paclitaxel and Trastuzumab for early-stage HER2-positive breast cancer experienced mild to moderate hair loss.

This study found that many young women with breast cancer experience a poor quality of life over time, especially regarding sexual health, future perspective, and hair loss.

An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.

This review discusses the paradoxical effects of valproic acid on hair, noting that it can both cause alopecia and stimulate hair growth, but reports no new experimental findings.

This study found that the expression of certain biomarkers, including HER-2 and oestrogen receptor alpha, in breast skin may be influenced by the presence of breast cancer, suggesting a systemic effect.

This retrospective study observed that breast cancer treatments disrupted normal blood counts and led to bone marrow suppression, highlighting the need for nutritional counseling to improve patient quality of life.

In this study, the researchers found that different CDK4/6 inhibitors used in treating HR+/HER2- advanced breast cancer have varying safety profiles and impacts on patient quality of life.

This study reports a case of a 28-year-old woman diagnosed with metastatic breast cancer through bone marrow analysis using flow cytometry and immunohistochemistry, highlighting the potential of flow cytometry as a valuable diagnostic tool for detecting solid tumors.

This source reports that trastuzumab deruxtecan improves outcomes in HER2-positive and HER2-low metastatic breast cancer, emphasizing the need for careful adverse event monitoring, particularly for interstitial lung disease, and managing emetic risk to maximize benefits.

This study found that CDK4/6 inhibitors for HR+/HER2- advanced breast cancer are linked to typical adverse events such as fatigue and neutropenia, while also identifying unexpected reactions, highlighting potential safety concerns in their real-world use.